[The expression technology of chimeric and humanized antibodies].
Since the discovery of monoclonal antibody(MoAb) in 1975, MoAbs have held great promise for the treatment of human disease such as cancer, viral infection, and autoimmune disorders. The most important limitations in murine MoAb have been the immune response against murine immunoglobulins and insufficient activation of human effector function. The emergence of antibodies as an attractive therapy is the result of the evolution of MoAb technology over the past 25 years. These problems have been overcome using genetic engineering techniques to produce chimeric mouse-human, CDR-grafted, and fully human antibodies. New strategies to develop chimeric, humanized, and completely human antibodies are discussed in this review.
Ishida
Tadao
T
First Department of Internal Medicine, Sapporo Medical University.
Imai
Kohzoh
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000737:chemistry; D022801:Complementarity Determining Regions / Q000235:genetics; D006801:Humans; D007127:Immunoglobulin Constant Regions / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D008970:Molecular Weight; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis* / Q000737:chemistry
D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D007127:Immunoglobulin Constant Regions; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins